Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 59 results.
LastUpdate Updated on 14/07/2025 [07:33:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Results 50 to 59 of 59  

SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES

Publication No.:  US2025164471A1 22/05/2025
Applicant: 
THE BRIGHAM AND WOMENS HOSPITAL INC [US]
THE BRIGHAM AND WOMEN'S HOSPITAL, INC
US_2024361307_PA

Absstract of: US2025164471A1

The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

METHOD OF INHIBITING TAU PHOSPHORYLATION

Publication No.:  US2025163372A1 22/05/2025
Applicant: 
CASSAVA SCIENCES INC [US]
Cassava Sciences, Inc
US_2025092361_A1

Absstract of: US2025163372A1

A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT

Publication No.:  US2025163135A1 22/05/2025
Applicant: 
EISAI R&D MAN CO LTD [JP]
Eisai R&D Management Co., Ltd
MX_2023015183_A

Absstract of: US2025163135A1

Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

METHODS OF ASSESSING DEMENTIA RISK

Publication No.:  EP4555327A1 21/05/2025
Applicant: 
SOMALOGIC OPERATING CO INC [US]
SomaLogic Operating Co., Inc
AU_2023308198_A1

Absstract of: AU2023308198A1

The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.

신경변성 질병과 관련된 신경변성의 감소 방법

Publication No.:  KR20250070087A 20/05/2025
Applicant: 
에자이알앤드디매니지먼트가부시키가이샤워싱톤유니버시티
CN_120076808_A

Absstract of: AU2023347307A1

The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.

METHODS FOR DETECTION OF CELL-FREE DNA (CFDNA) AND USES THEREOF FOR DIAGNOSING, TREATING, AND/OR MONITORING ALZHEIMER'S DISEASE

Publication No.:  AU2023371615A1 15/05/2025
Applicant: 
SEQ BIOMARQUE LLC
THE JOHNS HOPKINS UNIV
SEQ BIOMARQUE, LLC,
THE JOHNS HOPKINS UNIVERSITY
AU_2023371615_PA

Absstract of: AU2023371615A1

Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.

NOVEL METHOD

Publication No.:  WO2025099457A2 15/05/2025
Applicant: 
CAMBRIDGE ENTERPRISE LTD [GB]
CAMBRIDGE ENTERPRISE LIMITED
WO_2025099457_PA

Absstract of: WO2025099457A2

The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.

CALIBRATOR

Publication No.:  WO2025099460A1 15/05/2025
Applicant: 
CAMBRIDGE ENTERPRISE LTD [GB]
CAMBRIDGE ENTERPRISE LIMITED
WO_2025099460_PA

Absstract of: WO2025099460A1

The invention relates to calibration standards for use in a single-molecular detection methods, in particular to quantify protein complexes in a sample.

NOVEL METHOD

Nº publicación: WO2025099458A1 15/05/2025

Applicant:

CAMBRIDGE ENTERPRISE LTD [GB]
CAMBRIDGE ENTERPRISE LIMITED

WO_2025099458_PA

Absstract of: WO2025099458A1

The invention relates to methods of determining whether a subject has, or is at risk of developing, a neurodegenerative disorder using ultra-sensitive techniques, in particular a single-molecular array detection method.

traducir